Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
LORELCO is an oral small-molecule tablet approved by the FDA in 1977 for an undisclosed indication(s). As a legacy NDA product, it represents a mature therapeutic asset within Sanofi's portfolio with established clinical utility.
As a mature product approaching loss of exclusivity with moderate competitive pressure (30/100), commercial teams are likely focused on lifecycle extension or transition planning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Bioequivalence Study Comparing a Single Oral Intake of an Imported PROBUCOL Tablet(Lorelco) With a Marketed PROBUCOL Tablet(Chang Tai) in Chinese Healthy Volunteers
LORELCO currently shows zero linked job openings, reflecting its mature lifecycle and approaching LOE. Career opportunities on this asset are limited; professionals should consider it a maintenance/legacy role rather than a growth platform.
Worked on LORELCO at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.